Expression Level of the PPP2R5C Gene in Patients With Acute Myeloid Leukemia and Chronic Myeloid Leukemia

Background: One of the most important B-subunits of protein phosphatase 2A (PP2A) is PPP2R5C, which is involved in both the sup- pression and promotion of cell growth. Objectives: With regard to this vital role of PPP2R5C, we will examine whether alteration in expression of some proteins is involved in signal transduction, for example the B-subunit of protein phosphatases can be observed in patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). MaterialsandMethods: We recruited 50 patients with AML and 31 patients with CML, together with 23 individuals in the control group. The expression levels of PPP2R5C and the reference gene B2-MG were determined by SYBR green I real-time PCR. The 2 (- CT) method was used to present the data of the genes of interest relative to an internal control gene. Results: In this study, significantly higher expression of PPP2R5C was found in the AML (4.13 4.85) compared with healthy individuals. The expression level of PPP2R5C significantly decreased (0.469 0.34) in CML patients compared with healthy individuals. Conclusions: With regard to the critical role of PPP2R5C B-subunit on regulation of PP2A, the change in the expression pattern of PPP2R5C may be a critical finding in AML and CML patients, because it could be a cause of abnormal cell proliferation, dierentiation, and transformation in these two groups of patients.

[1]  M. Copland,et al.  Novel drug therapies in myeloid leukemia. , 2015, Pharmaceutical patent analyst.

[2]  Na Li,et al.  Over-Expression of Cancerous Inhibitor of PP2A (CIP2A) in Bone Marrow Cells from Patients with a Group of High-Risk Myelodysplastic Syndromes , 2014, Pathology & Oncology Research.

[3]  Yitao Ding,et al.  PP2A-Mediated Anticancer Therapy , 2013, Gastroenterology research and practice.

[4]  Shaohua Chen,et al.  Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells. , 2013, DNA and cell biology.

[5]  Shaohua Chen,et al.  Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation , 2013, Journal of Hematology & Oncology.

[6]  Xuan Liu,et al.  B56γ Tumor-Associated Mutations Provide New Mechanisms for B56γ-PP2A Tumor Suppressor Activity , 2013, Molecular Cancer Research.

[7]  X. Liu,et al.  ATM-mediated phosphorylation activates the tumor-suppressive function of B56γ–PP2A , 2011, Oncogene.

[8]  Shaohua Chen,et al.  Expression and distribution of PPP2R5C gene in leukemia , 2011, Journal of hematology & oncology.

[9]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging , 2011, Aging.

[10]  A. Kohlmann,et al.  Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. , 2010, Cancer treatment reviews.

[11]  Cheng-Wei Wu,et al.  The B56γ3 Regulatory Subunit of Protein Phosphatase 2A (PP2A) Regulates S Phase-specific Nuclear Accumulation of PP2A and the G1 to S Transition* , 2010, The Journal of Biological Chemistry.

[12]  Xuan Liu,et al.  A B56γ mutation in lung cancer disrupts the p53-dependent tumor suppressor function of protein phosphatase 2A , 2010, Oncogene.

[13]  X. Chen,et al.  PR55α, a Regulatory Subunit of PP2A, Specifically Regulates PP2A-mediated β-Catenin Dephosphorylation , 2009, The Journal of Biological Chemistry.

[14]  W. Hahn,et al.  Multiple pathways regulated by the tumor suppressor PP2A in transformation. , 2008, Trends in molecular medicine.

[15]  A. Newton,et al.  The Phosphatase PHLPP Controls the Cellular Levels of Protein Kinase C* , 2008, Journal of Biological Chemistry.

[16]  H. Helenius,et al.  Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia , 2008, European journal of haematology.

[17]  Xin Cai,et al.  Serine 15 Phosphorylation of p53 Directs Its Interaction with B56γ and the Tumor Suppressor Activity of B56γ-Specific Protein Phosphatase 2A , 2007, Molecular and Cellular Biology.

[18]  M. Mumby.  PP2A: Unveiling a Reluctant Tumor Suppressor , 2007, Cell.

[19]  D. Morrison,et al.  Integrating signals from RTKs to ERK/MAPK , 2007, Oncogene.

[20]  D. Perrotti,et al.  ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia , 2006, British Journal of Cancer.

[21]  H. Tagawa,et al.  Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. , 2006, Blood.

[22]  W. Hahn,et al.  Involvement of PP2A in viral and cellular transformation , 2005, Oncogene.

[23]  Guido Marcucci,et al.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. , 2005, Cancer cell.

[24]  G. Gahrton,et al.  Identification of progression markers in B-CLL by gene expression profiling. , 2005, Experimental hematology.

[25]  C. van Hoof,et al.  PP2A: the expected tumor suppressor. , 2005, Current opinion in genetics & development.

[26]  K. Isobe,et al.  Protein phosphatase 1, but not protein phosphatase 2A, dephosphorylates DNA‐damaging stress‐induced phospho‐serine 15 of p53 , 2004, FEBS letters.

[27]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[28]  W. Hahn,et al.  Identification of specific PP2A complexes involved in human cell transformation. , 2004, Cancer cell.

[29]  C. Whiteford,et al.  Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage , 2004, Oncogene.

[30]  C. van Hoof,et al.  Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. , 2003, Biochimica et biophysica acta.

[31]  A. Zeiher,et al.  Regulation of telomerase activity and anti‐apoptotic function by protein–protein interaction and phosphorylation , 2003, FEBS letters.

[32]  David L. Brautigan,et al.  The Specificity of Extracellular Signal-regulated Kinase 2 Dephosphorylation by Protein Phosphatases* , 2002, The Journal of Biological Chemistry.

[33]  S. Thorgeirsson,et al.  Cyclin G recruits PP2A to dephosphorylate Mdm2. , 2002, Molecular cell.

[34]  J. Minna,et al.  Genomic Organization and Mapping of the Gene Encoding the PP2A B56γ Regulatory Subunit , 2002 .

[35]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[36]  A. Schönthal,et al.  Role of serine/threonine protein phosphatase 2A in cancer. , 2001, Cancer letters.

[37]  E. Sontag.  Protein phosphatase 2A: the Trojan Horse of cellular signaling. , 2001, Cellular signalling.

[38]  G. Muszyńska,et al.  Protein phosphatase 2A: variety of forms and diversity of functions. , 2001, Acta biochimica Polonica.

[39]  Z. Damuni,et al.  The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A (*) , 1996, The Journal of Biological Chemistry.

[40]  G. Bloom,et al.  A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle , 1995, The Journal of cell biology.

[41]  P. Cohen,et al.  Inactivation of p42 MAP kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL100, in various cell lines , 1995, Current Biology.